

Anti-TNFSF14/LIGHT/CD258 Antibody (SAR252067)

Introduction

Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a humanized monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in COVID-19 acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS). Quisovalimab can be used in studies such as COVID-19 acute respiratory distress syndrome.

Product parameters

Alternative Names	AVTX-002, CERC-002, AEVI-002
Target Accession	Q92956
Target	TNFSF14 / LIGHT / CD258
CAS number	2427667-03-4
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

